維昇藥業-B(2561.HK)IPO火爆逾70倍超購:基石陣容豪華
維昇藥業股份有限公司(簡稱“維昇藥業”,代碼02561)發行價格為每股68.80港幣,基礎融資規模1億美元(含擴大發行規模15%),綠鞋規模1500萬美元(基礎發行規模的15%),將於3月21日正式上市。據悉,招股期截止時,預計其公開發售部分獲得近70倍超額認購,國際發售部分同時獲得超額申購。維昇藥業此次IPO引入了5名基石投資者,包括安科生物、蘇州工業園區產業投資基金、Vivo Capital、藥明生物、Reynold Lemkins等。維昇藥業此次IPO受到市場高度認可,其背後還有多重因素推動。首先,維昇藥業自身實力強勁,專注於內分泌疾病治療領域,擁有強大的產品管線。其核心產品隆培促生長素的上市許可申請已獲中國國家藥品監督管理局受理,商業化在即,同時還擁有多款內分泌治療領域的潛在FIC/BIC候選藥物,具有廣闊的市場前景。近日,維昇藥業的大股東Ascendis Pharma在美上市的股票價格逆勢創出年內新高。有市場人士分析指出,除了Ascendis最新一期業績表現優異等因素外,獲得多家大行提升目標價也是其市場關注度提升的原因之一。市場或憧憬於維昇藥業上市後,Ascendis隱含持股價值有機會得到重估。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.